At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,107 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA® (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice
In Brief
An observational study for Crohn's Disease. Completed, enrolled 4,107 participants.
Detailed Summary
The purpose of this study was intended to evaluate the long-term safety and effectiveness of adalimumab in participants with Crohn's disease (CD) who are treated as recommended in the product label.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMar 2010
Primary CompletionDec 2015
TodayJul 2026
First PostedMar 10, 2010
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 16.3 years ago